The Tromsø study 1974–2016: 40 years of cardiovascular research

References

• Jervell A, Meyer K, Westlund K. Coronary heart disease and serum cholesterol in males in different parts of Norway. Acta Med Scand. 1965;177:13–23.
   PubMedGoogle Scholar
• Hjermann I, Velve Byre K, Holme I, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet. 1981;2:1303–1310.
   PubMed Web of Science ®Google Scholar
• Bjartveit K, Foss OP, Gjervig T, et al. The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl. 1979;634:1–70.
   PubMedGoogle Scholar
• Thelle DS, Førde OH, Try K, et al. The Tromsø heart study. Methods and main results of the cross-sectional study. Acta Med Scand. 1976;200:107–118.
   PubMedGoogle Scholar
• Miller NE, Thelle DS, Førde OH, et al. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965–968.
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–714.
   PubMed Web of Science ®Google Scholar
• Førde OH, Thelle DS, Miller NE, et al. The Tromsø heart study. Distribution of serum cholesterol between high density and lower density lipoproteins in subjects of Norse, Finnish and Lappish ethnic origin. Acta Med Scand. 1978;203:21–26.
   PubMedGoogle Scholar
• Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–580.
   PubMed Web of Science ®Google Scholar
• Thelle DS, Arnesen E, Førde OH. The Tromsø heart study. Does coffee raise serum cholesterol? N Engl J Med. 1983;308:1454–1457.
   PubMed Web of Science ®Google Scholar
• Arnesen E, Førde OH, Thelle DS. Coffee and serum cholesterol. Br Med J (Clin Res Ed). 1984;288:1960.
   PubMed Web of Science ®Google Scholar
• Bønaa K, Arnesen E, Thelle DS, et al. Coffee and cholesterol: is it all in the brewing? The Tromsø study. BMJ. 1988;297:1103–1104.
   PubMed Web of Science ®Google Scholar
• Weusten-Van der Wouw MP, Katan MB, Viani R, et al. Identity of the cholesterol-raising factor from boiled coffee and its effects on liver function enzymes. J Lipid Res. 1994;35:721–733.
   PubMed Web of Science ®Google Scholar
• Strandhagen E, Zetterberg H, Aires N, et al. The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee. Lipids Health Dis. 2004;3:26.
   PubMedGoogle Scholar
• Hopstock LA, Wilsgaard T, Njølstad I, et al. Seasonal variation in incidence of acute myocardial infarction in a sub-Arctic population: the Tromsø study 1974–2004. Eur J Cardiovasc Prev Rehabil. 2011;18:320–325.
   PubMedGoogle Scholar
• Jacobsen BK, Thelle DS. Risk factors for coronary heart disease and level of education. The Tromsø Heart Study. Am J Epidemiol. 1988;127:923–932.
   PubMed Web of Science ®Google Scholar
• Eggen AE, Mathiesen EB, Wilsgaard T, et al. Trends in cardiovascular risk factors across levels of education in a general population: is the educational gap increasing? The Tromsø study 1994–2008. J Epidemiol Community Health. 2014;68:712–719.
   PubMed Web of Science ®Google Scholar
• Hopstock LA, Bønaa KH, Eggen AE, et al. Longitudinal and secular trends in blood pressure among women and men in birth cohorts born between 1905 and 1977: the Tromsø study. Hypertension. 2015;66:496–501.
   PubMed Web of Science ®Google Scholar
• Grimby G, Börjesson M, Jonsdottir IH, et al. The “Saltin-Grimby Physical Activity Level Scale” and its application to health research. Scand J Med Sci Sports. 2015;25:119–125.
   PubMed Web of Science ®Google Scholar
• Morseth B, Jørgensen L, Emaus N, et al. Tracking of leisure time physical activity during 28 yr in adults: the Tromsø study. Med Sci Sports Exerc. 2011;43:1229–1234.
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–162.
   PubMed Web of Science ®Google Scholar
• Løchen ML. The Tromsø study: associations between self-reported arrhythmia, psychological conditions, and lifestyle. Scand J Prim Health Care. 1991;9:265–270.
   PubMedGoogle Scholar
• Nyrnes A, Mathiesen EB, Njølstad I, et al. Palpitations are predictive of future atrial fibrillation. An 11-year follow-up of 22,815 men and women: the Tromsø study. Eur J Prev Cardiol. 2013;20:729–736.
   PubMed Web of Science ®Google Scholar
• Morseth B, Graff-Iversen S, Jacobsen BK, et al. Physical activity, resting heart rate, and atrial fibrillation: the Tromsø study. Eur Heart J. 2016;37:2307–2313.
   PubMed Web of Science ®Google Scholar
• Schirmer H, Lunde P, Rasmussen K. What determines echogenicity in a general population? The Tromsø study. J Am Soc Echocardiogr. 1999;12:314–318.
   PubMed Web of Science ®Google Scholar
• Eveborn GW, Schirmer H, Heggelund G, et al. Incidence of aortic stenosis in subjects with normal and slightly elevated aortic gradients and flow. Heart. 2015;101:1895–1900.
   PubMed Web of Science ®Google Scholar
• Eveborn GW, Schirmer H, Lunde P, et al. Assessment of risk factors for developing incident aortic stenosis: the Tromsø study. Eur J Epidemiol. 2014;29:567–575.
   PubMed Web of Science ®Google Scholar
• Tiwari S, Schirmer H, Jacobsen BK, et al. Association between diastolic dysfunction and future atrial fibrillation in the Tromsø study from 1994 to 2010. Heart. 2015;101:1302–1308.
   PubMed Web of Science ®Google Scholar
• Tiwari S, Løchen ML, Jacobsen BK, Hopstock LA, Nyrnes A, Njølstad I, et al. CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromsø Study. Open Heart. 2016;3:e000439.
   Google Scholar
• Stensland-Bugge E, Bønaa KH, Joakimsen O, et al. CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromsø Study. Open Heart. 2016;3:e000439.
   Google Scholar
• Johnsen SH, Fosse E, Joakimsen O, et al. Monocyte count is a predictor of novel plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromsø study. Stroke. 2005;36:715–719.
   PubMed Web of Science ®Google Scholar
• Johnsen SH, Mathiesen EB, Fosse E, et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromsø study. Circulation. 2005;112:498–504.
   PubMed Web of Science ®Google Scholar
• Spence JD. Measurement of intima-media thickness vs. carotid plaque: uses in patient care, genetic research and evaluation of new therapies. Int J Stroke. 2006;1:216–221.
   PubMed Web of Science ®Google Scholar
• Johnsen SH, Mathiesen EB. Carotid plaque compared with intima-media thickness as a predictor of coronary and cerebrovascular disease. Curr Cardiol Rep. 2009;11:21–27.
   PubMedGoogle Scholar
• Mathiesen EB, Johnsen SH, Wilsgaard T, et al. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke: a 10-year follow-up of 6584 men and women: the Tromsø study. Stroke. 2011;42:972–978.
   PubMed Web of Science ®Google Scholar
• Mathiesen EB, Bønaa KH, Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the Tromsø study. Stroke. 2001;32:1960–1965.
   PubMed Web of Science ®Google Scholar
• Arntzen KA, Schirmer H, Johnsen SH, et al. Carotid atherosclerosis predicts lower cognitive test results: a 7-year follow-up study of 4,371 stroke-free subjects – the Tromsø study. Cerebrovasc Dis. 2012;33:159–165.
   PubMed Web of Science ®Google Scholar
• Arntzen KA, Schirmer H, Johnsen SH, et al. Carotid artery plaque progression and cognitive decline: the Tromsø study 1994–2008. Eur J Neurol. 2012;19:1318–1324.
   PubMed Web of Science ®Google Scholar
• Rogne SO, Solbu MD, Arntzen KA, et al. Albuminuria and carotid atherosclerosis as predictors of cognitive function in a general population. Eur Neurol. 2013;70:340–348.
   PubMed Web of Science ®Google Scholar
• Borch KH, Brækkan SK, Mathiesen EB, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study. J Thromb Haemost. 2009;7:739–745.
   PubMed Web of Science ®Google Scholar
• Mannsverk J, Wilsgaard T, Njolstad I, et al. Age and gender differences in incidence and case fatality trends for myocardial infarction: a 30-year follow-up. The Tromsø study. Eur J Prev Cardiol. 2012;19:927–934.
   PubMed Web of Science ®Google Scholar
• Mannsverk J, Wilsgaard T, Mathiesen EB, et al. Trends in modifiable risk factors are associated with declining incidence of hospitalized and nonhospitalized acute coronary heart disease in a population. Circulation. 2016;133:74–81.
   PubMed Web of Science ®Google Scholar
• Jorde R, Schirmer H, Wilsgaard T, et al. Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø study. PLoS One. 2012;7:e37295.
   PubMed Web of Science ®Google Scholar
• Wilsgaard T, Mathiesen EB, Patwardhan A, et al. Clinically significant novel biomarkers for prediction of first ever myocardial infarction: the Tromsø study. Circ Cardiovasc Genet. 2015;8:363–371.
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet. 2009;41:876.
   PubMed Web of Science ®Google Scholar
• Poppe KK, Doughty RN, Whalley GA. Redefining normal reference ranges for echocardiography: a major new individual person data meta-analysis. Eur Heart J Cardiovasc Imag. 2013;14:347–348.
   PubMed Web of Science ®Google Scholar
• Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study. JACC Cardiovasc Imag. 2015;8:656–665.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.
   PubMed Web of Science ®Google Scholar
• Prospective Studies C. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–1096.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Prospective Studies C, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Bjerve KS, Straume B, et al. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromsø study. N Engl J Med. 1990;322:795–801.
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Thelle DS. Association between blood pressure and serum lipids in a population. The Tromsø study. Circulation. 1991;83:1305–1314.
   PubMed Web of Science ®Google Scholar
• Arnesen E, Refsum H, Bønaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704–709.
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588.
   PubMed Web of Science ®Google Scholar